These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 21956947)
1. Modeling data with structural and temporal correlation using lower level and higher level multilevel models. James G; Zhou Y; Miller S Pharm Stat; 2011; 10(5):395-406. PubMed ID: 21956947 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Berry DA; Berry SM; McKellar J; Pearson TA Am Heart J; 2003 Jun; 145(6):1036-45. PubMed ID: 12796760 [TBL] [Abstract][Full Text] [Related]
3. Multilevel modeling: current and future applications in personality research. West SG; Ryu E; Kwok OM; Cham H J Pers; 2011 Feb; 79(1):2-50. PubMed ID: 21223263 [TBL] [Abstract][Full Text] [Related]
4. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Peissig P; Sirohi E; Berg RL; Brown-Switzer C; Ghebranious N; McCarty CA; Wilke RA Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):286-8. PubMed ID: 17371534 [No Abstract] [Full Text] [Related]
5. [Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)]. Nissen S MMW Fortschr Med; 2004 Mar; 146(13):65. PubMed ID: 15219143 [No Abstract] [Full Text] [Related]
6. Conducting multilevel analyses in medical education. Zyphur MJ; Kaplan SA; Islam G; Barsky AP; Franklin MS Adv Health Sci Educ Theory Pract; 2008 Dec; 13(5):571-82. PubMed ID: 17932779 [TBL] [Abstract][Full Text] [Related]
7. Atorvastatin--a new lipid-lowering drug. Med Lett Drugs Ther; 1997 Mar; 39(997):29-31. PubMed ID: 9121394 [No Abstract] [Full Text] [Related]
8. Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches. Catapano AL; Norata GD; Pirillo A Curr Opin Lipidol; 2011 Aug; 22(4):324-5. PubMed ID: 21743311 [No Abstract] [Full Text] [Related]
9. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535 [TBL] [Abstract][Full Text] [Related]
10. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151 [TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. Wang ZH; Liu XL; Zhong M; Zhang LP; Shang YY; Hu XY; Li L; Zhang Y; Deng JT; Zhang W J Clin Pharmacol; 2010 Mar; 50(3):311-9. PubMed ID: 19808950 [TBL] [Abstract][Full Text] [Related]
12. Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Adams GJ; Greene J; Vick GW; Harrist R; Kimball KT; Karmonik C; Ballantyne CM; Insull W; Morrisett JD Magn Reson Imaging; 2004 Nov; 22(9):1249-58. PubMed ID: 15607096 [TBL] [Abstract][Full Text] [Related]
13. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609 [TBL] [Abstract][Full Text] [Related]
14. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. Parolini C; Marchesi M; Lorenzon P; Castano M; Balconi E; Miragoli L; Chaabane L; Morisetti A; Lorusso V; Martin BJ; Bisgaier CL; Krause B; Newton RS; Sirtori CR; Chiesa G J Am Coll Cardiol; 2008 Mar; 51(11):1098-103. PubMed ID: 18342229 [TBL] [Abstract][Full Text] [Related]
15. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S; J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447 [TBL] [Abstract][Full Text] [Related]
16. A general multilevel SEM framework for assessing multilevel mediation. Preacher KJ; Zyphur MJ; Zhang Z Psychol Methods; 2010 Sep; 15(3):209-33. PubMed ID: 20822249 [TBL] [Abstract][Full Text] [Related]
17. [Decreasing blood lipids for prevention of coronary heart disease--discussion of the "permissive LDL level". Diagnostic imaging facilitates therapeutic decision]. MMW Fortschr Med; 2001 Mar; 143(13):48-9. PubMed ID: 11332020 [No Abstract] [Full Text] [Related]
18. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. Martín-Ventura JL; Tuñon J; Duran MC; Blanco-Colio LM; Vivanco F; Egido J J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S189-93. PubMed ID: 17130260 [TBL] [Abstract][Full Text] [Related]
19. Atorvastatin: a new agent for hyperlipidemia. Kupecz D Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876 [No Abstract] [Full Text] [Related]